|WHEN||October 10, 2017 - October 10, 2017 @ 5:30pm - 8:00pm|
|WHERE||Jones Day, 4655 Executive Drive, Suite 1500, San Diego, CA 92121|
|INFO||Free online registration by Sunday, Oct 6th, 2017 (limit 70 attendees); $10 onsite registration|
Dr. Dale L. Rieger is a patent attorney and partner at Jones Day. Dr. Rieger counsels clients in all aspects of patent portfolio development, particularly in the field of chemistry including pharmaceuticals, agrochemicals, and polymers. He advises pharmaceutical and biotechnology companies regarding pharmaceutical lifecycle management and Hatch-Waxman patent term extensions and litigation. He also advises corporate and venture investors on intellectual property due diligence associated with mergers and acquisitions, joint ventures, private and public financings, and initial public offerings.
Dr. Rieger’s legal and scientific career has emphasized pharmaceuticals, particularly working with small molecule drugs. Before joining Jones Day, he worked at Agouron Pharmaceuticals as a senior scientist, at Gensia as a senior research scientist, and at Merck Research Laboratories as a senior research chemist. Dr. Rieger received a Ph.D. in Organic Chemistry from Indiana University and was a postdoctoral fellow at Harvard. Dr. Rieger will discuss patent portfolio management and Orange Book listing of small-molecule drug patents.
Dr. Cary Miller is a patent attorney and partner at Jones Day. With more than 15 years of experience, Dr. Miller’s practice focuses on assisting life sciences clients with their patent issues. She works with clients in patent prosecution, prelitigation analysis, PTAB proceedings, and patent litigation. Dr. Miller’s currently represents Celgene in several Hatch-Waxman patent litigations involving the pharmaceuticals Abraxane®, Pomalyst®, and Revlimid®. Previously, Dr. Miller’s participated in numerous biotechnology and pharmaceutical patent lawsuits including representing companies in Hatch-Waxman litigation, biosimilars litigation, and in litigation relating to DNA sequencing. She has successfully litigated patent cases throughout the United States, including in California, New Jersey, New York, Delaware, Texas, and Nevada and before the Federal Circuit and Supreme Court. Dr. Miller has drafted and prosecuted patents relating to breakthrough therapies in a number of areas, including antibodies and antibody-drug conjugates, cancer therapeutics and diagnostics, small molecules, human embryonic stem cells, and drug delivery devices. She has conducted intellectual property due diligence studies and has filed numerous patent term extension applications for drugs, biologics, and medical devices. Dr. Miller received a Ph.D. in in cellular, developmental, and molecular biology from Mount Sinai School of Medicine. Dr. Miller will discuss patent term extension (PTE) and FDA exclusivities.
5:30 to 6:20 pm: Registration and Networking dinner
6:20 to 6:30 pm: Welcome by Peter Huang, PhD, President-elect of SABPA
6:30 to 7:30 pm: Dr. Dale L. Rieger Patent portfolio management and Orange Book listing of small-molecule drug patents
Dr. Cary Miller Patent term extension (PTE) and FDA exclusivities
7:30 to 8:00 pm: Networking
SABPA entrepreneur committee
Annie Mak, Ph.D.
Jie Jiang, Ph.D.
Jones Day – One Firm Worldwide
Lin Yu, Ph.D., Esq.
Post Event Report
The 20th SABPA Entrepreneur Symposium took place at the La Jolla office of Jones Day on Oct 10, 2017. Two partners of Jones Day, Dr. Dale Rieger and Dr. Cary Miller, discussed IP strategies to maximize protection of biotech and pharmaceutical products. The event was attended by over 70 scientists and entrepreneurs from the local San Diego community.
Dr. Dale Rieger gave a presentation on patent portfolio management for a pharmaceutical product and the Orange Book listing of small-molecule drug patents. He emphasized that valuable intellectual property could be obtained at every step along the drug discovery timeline.
Dr. Cary Miller discussed patent term extension (PTE) and FDA exclusivities. PTE is based on the same quid pro quo spirit of patents: FDA will grant extensions to patent terms to recover the period of time spent on product approval process. While multiple PTE applications could be filed, only one PTE could normally be applied to a single product. Dr. Miller highlighted that FDA exclusivities are important for IP portfolio management in that the exclusivity time period can fend off the competition from generics. She introduced various kinds of exclusivities and the respective coverage and periods, and explained how patent, Orange Book listing and exclusivity can interplay in terms of IP protection.
Dr. Rieger and Dr. Miller generously commented and answered questions from the audience on the topics covered. The audience appreciated their thoughtful comments and sharing their viewpoints, and the lively discussion continued well beyond the scheduled time.